<DOC>
	<DOCNO>NCT00182663</DOCNO>
	<brief_summary>This phase II trial study side effect well give thalidomide , dexamethasone , clarithromycin together work treat patient multiple myeloma previously treat transplant . Biological therapy , thalidomide clarithromycin , may stimulate immune system different way stop cancer cell grow . Dexamethasone also work different way stop growth cancer cell , either kill cell stop divide . Giving thalidomide together dexamethasone clarithromycin transplant may effective treatment multiple myeloma</brief_summary>
	<brief_title>Thalidomide , Dexamethasone , Clarithromycin Treating Patients With Multiple Myeloma Previously Treated With Transplant</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate toxicity use Thalidomide/Biaxin ( Clarithromycin ) /Dexamethasone maintenance therapy autologous/syngeneic transplant . II . Evaluate median time disease progression . III . Evaluate survival . OUTLINE : Patients receive thalidomide orally ( PO ) daily ( QD ) , dexamethasone PO weekly , clarithromycin PO twice daily ( BID ) . Treatment continue 1 year absence disease progression unacceptable toxicity . Treatment thalidomide continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Any autologous syngeneic patient underwent high dose melphalan ( &gt; = 140 mg/m^2 ) therapy/peripheral blood stem cell ( PBSC ) bone marrow ( BM ) rescue stage multiple myeloma participate another clinical transplant trial also evaluate disease free survival survival Platelet count ( transfusion independent ) &gt; 50,000 cells/mm^3 5 calendar day recovery high dose Absolute granulocyte count &gt; 1500 cells/mm^3 5 calendar day recovery high dose Patients start therapy 30 day 120 day transplant Willingness ability comply Food Drug Administration ( FDA ) mandate S.T.E.P.S . ( Celgene System Thalidomide Education Prescribing Safety ) Program Signing write informed consent form Karnofsky score less 70 A leave ventricular ejection fraction le 45 % ; patient congestive heart disease , history myocardial infarction ( MI ) , coronary artery disease Total bilirubin great 2 mg/ml ( unless history Gilbert 's disease ) Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) &gt; 2.5 x upper limit normal History deep venous thrombus , arterial occlusion , pulmonary embolus Pregnant and/or lactate female Patients give informed consent Patients untreated systemic infection Patients history prior transplant treatment combination therapy Thalidomide/Biaxin Steroid without response Patients allergic Thalidomide , Biaxin Dexamethasone Referring physician register S.T.E.P.S . program unwilling oversee care patient study comply FDAmandated S.T.E.P.S . Program Patients unwilling practice adequate form contraception clinically indicate ; male patient study need consult use latex condom even vasectomy every time sex woman able child treat four week stop drug Patients history seizure</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>